HIV/AIDS
New HIV/AIDS study results from A. Cozzilepri et al described
Published in AIDS Weekly, September 21st, 2009
"Because changes in antiretroviral therapy in resource-limited settings (RLSs) are delayed until patients experience immunological or clinical failure, it is important to be able to estimate the consequences in terms of accumulation of thymidine analogue ( TA) mutations (TAMs). The study included patients in EuroSIDA with >= 2 available genotypic resistance tests (GRTs) ( human immunodeficiency virus [HIV] RNA level, 1500 copies/mL in any measure between tests), provided that the first GRT was performed after the first virological failure of a TA and that the same TA was continued until the second GRT," investigators in London, the United Kingdom report.
"At the time...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2009-09-21)
More Articles from AIDS Weekly
- HIV/AIDS
Data from M. Nijhuis et al provide new insights into HIV/AIDS - HIV/AIDS
Investigators at University of Washington publish new data on HIV/AIDS - HIV/AIDS
New findings from Yale University, Medical Department describe advances in HIV/AIDS - HIV/AIDS
New HIV/AIDS study findings have been published by S. Sonza and colleagues - HIV/AIDS
Research from J. Collazos and colleagues provide new insights into HIV/AIDS - HIV/AIDS
Research from New York Blood Center broadens understanding of HIV/AIDS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
